ArticleClinical & translational immunology2022
Parallel detection of SARS-CoV-2 epitopes reveals dynamic immunodominance profiles of CD8
Article in Clinical & translational immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 23 citations in OpenAlex.
- The ageing immune system and its battle with viruses.The Journal of general virology · 2026Review
- Systematic profiling of SARS-CoV-2 structural protein-specific T cell epitopes in Omicron infections following inactivated vaccination.iScience · 2026Article
- Central memory T cells with key TCR repertoires and gene expression profiles dominate influenza CD8+ T cell pools across the human lifespan.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Article
- Age and Latent Cytomegalovirus Infection Do Not Affect the Magnitude of De Novo SARS-CoV-2-Specific CD8European journal of immunology · 2025Article
- T Cell Peptide Prediction, Immune Response, and Host-Pathogen Relationship in Vaccinated and Recovered from Mild COVID-19 Subjects.Biomolecules · 2024Article
- T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination.Journal of neurology, neurosurgery, and psychiatry · 2024Article
- Article
- The demographic, laboratory and genetic factors associated with long Covid-19 syndrome: a case-control study.Clinical and experimental medicine · 2024Article
- Longevity of antibody responses is associated with distinct antigen-specific B cell subsets early after infection.Frontiers in immunology · 2024Article
- Tetanus-diphtheria vaccine can prime SARS-CoV-2 cross-reactive T cells.Frontiers in immunology · 2024Article
- Article
- Breadth and Durability of SARS-CoV-2-Specific T Cell Responses following Long-Term Recovery from COVID-19.Microbiology spectrum · 2023Article
- The Immune Response to SARS-CoV-2 Vaccine in a Cohort of Family Pediatricians from Southern Italy.Cells · 2023Article
- Cytokine Response Following SARS-CoV-2 Antigen Stimulation in Patients with Predominantly Antibody Deficiencies.Viruses · 2023Article
- Immunocytometric analysis of patients with thymic epithelial tumors revealed that COVID-19 vaccine booster strongly enhanced the immune response.Frontiers in immunology · 2023Article
- SARS-CoV-2 epitopes inform future vaccination strategies.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: High-magnitude CD8 Methods: CD8 Results: A comprehensive panel of 49 mostly conserved SARS-CoV-2-specific CD8 Conclusion: SARS-CoV-2 infection induces a predominant CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.